News

FDA Clears MAGNETOM Lumina 3T MRI System From Siemens Healthineers

70-cm Open Bore system with BioMatrix technology expands clinical application by delivering productivity gains and reproducible results.Innovision in-bore infotainment system designed to allow patients to enjoy various forms of media

Fri Feb 01 2019By Lindsay Orr

The Food and Drug Administration (FDA) has cleared the MAGNETOM Lumina 3 Tesla (3T) magnetic resonance imaging (MRI) scanner from Siemens Healthineers.

The MAGNETOM Lumina features BioMatrix patient personalization technology, which significantly improves productivity while ensuring consistent quality. The system has a wide, 70-cm bore and GO technologies powered by artificial intelligence (AI), which accelerate the entire MRI workflow. For example, a whole spine exam can be performed up to 20 percent faster compared to a conventional system. Tim 4G and Dot (Day Optimizing Throughput) engines support standardized, highly reproducible scan procedures. To further facilitate workflow efficiency, the system features an optional dockable table. Additionally, new Turbo Suite acceleration packages can further reduce scan time on routine musculoskeletal (MSK) examinations of various parts of the body by up to 50 percent.

The MAGNETOM Lumina will also offer the optional Innovision in-bore infotainment system, which is designed to move with the scanner table to not only create the illusion of an enlarged bore, but also to provide a unique video experience with excellent sound quality

“With the MAGNETOM Lumina, Siemens Healthineers is transforming care delivery by providing high performance with a strong return on investment,” said Jane Kilkenny, Vice President of Magnetic Resonance at Siemens Healthineers North America. “The patient experience is enhanced with a state-of-the-art infotainment system, lightweight and flexible coils, and new speed applications that enable the provider to get the patient on and off the table faster.”

 The in-bore Infotainment system Innovision is still under development and not yet commercially available. Its future availability cannot be guaranteed.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Please review our Privacy Policy for more details.
I Agree